“The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of nucleos(t)ide analogues with a high barrier to drug resistance (tenofovir and entecavir, and entecavir in children aged 2–11 years) for first- and second-line treatment,” said WHO on their website.
They also pose challenges to policymakers in low and middle-income countries to improve clinical outcomes, reduce HBV incidence and reduce stigma due to disease. Hepatitis B contributes to 650,000 deaths each year, and most those deaths are from the low and middle-income countries.
To read the full report, click here.
Read more news…
UMass Memorial, Shields Health Care Group plan freestanding surgery center
New legislation would remove ASCs from CON regulation in North Carolina
15 things to know about ASC valuation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
